SELLAS Life Sciences Group, Inc.

SLS
$8.97 (+ $1.38 + 18.18%)
Last updated: 2026-05-21 07:38 UTC
SLS Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS81642T1007
CUSIP81642T100
Market Price8.97
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.28
Market Cap$418.7M
Book Value0.36
Price to Book7.781
Beta2.52
52w High3.0
52w Low0.85
Next Earnings DateN/A

SELLAS Life Sciences Group, Inc. trades under ticker SLS on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US81642T1007, CUSIP 81642T100.

About the Company
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Price History